

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/627,413	07/25/2003	Arthur M. Krieg	C1039.70079US00	3204
75	90 06/01/2006		EXAM	INER
Helen C. Lockhart			LE, EMILY M	
Wolf, Greenfield & Sacks, P.C. Federal Reserve Plaza			ART UNIT	PAPER NUMBER
600 Atlantic Avenue			1648	
Boston, MA 0	2210	DATE MAILED: 06/01/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary		Application No.	Applicant(s)			
		10/627,413	KRIEG ET AL.			
		Examiner	Art Unit			
		Emily Le	1648			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHO WHIC - Exten after: - If NO - Failur Any ro	DRTENED STATUTORY PERIOD FOR REPLY HEVER IS LONGER, FROM THE MAILING DA sions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. period for reply is specified above, the maximum statutory period we to reply within the set or extended period for reply will, by statute, eply received by the Office later than three months after the mailing d patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status						
1)[🛛	Responsive to communication(s) filed on 25 Ju	<u>ly 2003</u> .				
2a) <u></u> □	This action is <b>FINAL</b> . 2b)⊠ This action is non-final.					
• —						
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Dispositi	on of Claims					
4)⊠ Claim(s) <u>42-71</u> is/are pending in the application.						
	4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.						
6)□	6)☐ Claim(s) is/are rejected.					
	Claim(s) is/are objected to.					
8)🖾	Claim(s) 42-71 are subject to restriction and/or	election requirement.				
Application Papers						
9) 🔲 -	The specification is objected to by the Examine	r. ,				
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) 🔲 .	The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.			
Priority u	nder 35 U.S.C. § 119					
•	Acknowledgment is made of a claim for foreign  ☐ All b) ☐ Some * c) ☐ None of:		)-(d) or (f).			
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rulè 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
		•				
Attachment	c(s)					
	e of References Cited (PTO-892)	4) Interview Summary				
3) Inform	e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) r No(s)/Mail Date	Paper No(s)/Mail Do 5) Notice of Informal F 6) Other:	ate Patent Application (PTO-152)			

Application/Control Number: 10/627,413 Page 2

Art Unit: 1648

## **DETAILED ACTION**

## Election/Restrictions

- 1. This application contains claims directed to the following patentably distinct species: A) 5'TCG-3'; B) 5'-purine, purine, C,G, pyrimidine, pyrimidine, C,C-3'; and C) 5'-purine, purine, C,G, pyrimidine, pyrimidine, C,G-3'.
- 2. Currently, independent claims 42, 50, 57, 64 and 68 are generic to species listed in A), B) and C).
- 3. If Applicant elects item B), Applicant is required to elect one of the following subspecies: a) 5'-GACGTTCC-3'; and b) SEQ ID NO: 3, wherein the sequence has 5'-AACGTTCC-3' motif.
- 4. Claims 44, 52, 59, 65 and 69 are generic to species a) and b).
- 5. If Applicant elects item b), Applicant is further required to elect one of the following sub-species: SEQ ID NOs: 7, 9-10, 35 and 54.
- 6. Claims 45, 53 and 60 are generic to the following species: SEQ ID NO: 7, 9-10, 35 and 54.
- 7. The species are independent or distinct because each of the listed species is not unified by a common utility. In the instant, each has a distinct Th-1 associated cytokine secretory profile. For example, SEQ ID NO: 3 induces IL-6, TNF-alpha, IFN-gamma, GM-CSF, and IL-12 secretion; and SEQ IDNO: 54 induces stimulation of B cell proliferation and IL-12.
- 8. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the

Art Unit: 1648

requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

- 9. The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.
- 10. Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.
- 11. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
- 12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Emily Le whose telephone number is (571) 272 0903. The examiner can normally be reached on Monday Friday, 8 am 5:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce R. Campell can be reached on (571) 272-0974. The fax phone

Application/Control Number: 10/627,413

Art Unit: 1648

number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Emily te ⊂ √ (Υໄ৹ Patent Examiner Art Unit 1648 Page 4